Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Novo recently acknowledged that the copycat GLP-1 market is of equal size to Novos business-probably attributable to the lower cost of compounded drugs
L., Wijayasinghe, N., & Norwood, P
In a retrospective study, researchers analyzed the number of acne vulgaris diagnoses among people with obesity but not diabetes who had been prescribed Saxenda (liraglutide), Wegovy (semaglutide), or Zepbound (tirzepatide)
US$ 20.64
US$ 24.28
US$ 26.39
US$ 28.49
US$ 26.35
